Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10351477 | 0.79 | KHK (0.43) | KHKCYP11B2CYP11B1TRPV4ESR1 | |
| SCHEMBL22120133 | 0.78 | KHK (0.41) | KHKCYP11B2CYP11B1TRPV4ESR1 | |
| SCHEMBL20597951 | 0.78 | KHK (0.41) | KHKCYP11B2CYP11B1TRPV4ESR1 | |
| SCHEMBL29560065 | 0.78 | TRPV4 (0.39) | KHKCYP11B2CYP11B1TRPV4ESR1 | |
| SCHEMBL504867 | 0.78 | TRPV4 (0.39) | KHKCYP11B2CYP11B1TRPV4ESR1 | |
| SCHEMBL585514 | 0.77 | CHRM5 (0.33) | ALDH1A1GPR35 | |
| SCHEMBL8663254 | 0.76 | KHK (0.47) | KHKCYP11B2CYP11B1TRPV4ESR1 | |
| SCHEMBL30670701 | 0.75 | TRPV4 (0.35) | KHKCYP11B2CYP11B1TRPV4SLC1A5 | |
| SCHEMBL9948817 | 0.75 | TRPV4 (0.35) | KHKCYP11B2CYP11B1TRPV4SLC1A5 | |
| SCHEMBL25190108 | 0.75 | CYP11B1 (0.37) | KHKCYP11B2CYP11B1TRPV4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136881-A | Organic compound, application thereof and organic electroluminescent device comprising same | 清华大学 | 2025-06-13 | — | — | CN | disclosed |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3898595-B1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII | 2022-09-15 | — | — | US | disclosed |
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | US | disclosed |
| EP-3898595-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | Merck Sharp & Dohme Corp. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113423695-A | Pyrimidinone derivatives as selective cytotoxic agents against HIV infected cells | 默沙东公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2021016333-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2020131597-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-110156637-A | A kind of preparation method of the chloro- 3- cyano -5- fluobenzoic acid of 2,4- bis- | 宁波美诺华药业股份有限公司 | 2019-08-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | TYMP, PNP, CD4 | KHK 3409/4885CYP11B2 3482/4885CYP11B1 3424/4885 |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | STAT3, JAK2, STAT6 | KHK 4000/4885CYP11B2 2772/4885CYP11B1 3094/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | KHK 3409/4885CYP11B2 3482/4885CYP11B1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.